Data MATRIX Ltd. Release: European Biotech Meets New Company
This April Data MATRIX is proud to join the Bavarian biotech cluster and open its’ German office for international clients. Data MATRIX is a qualified provider for software, data management and biostatistics services for clinical trials. It is now introducing to the European market its’ EDC/IWRS and CTMS products, based on the unique approach to software and high quality standards from Russian developers.
The company has been working with clinical data since 2009. The software applications are developed in-house by Data MATRIX, fully validated, 21 CFR part 11 and CDISC compliant. As of today, the team has conducted 134 projects for pharmaceutical and biotech companies and CROs.
With Data MATRIX products, 6 out of 10 TOP Big Pharma companies have already reduced their R&D costs by 15%. The company recently raised the investments for further development and expansion to EU ad US markets.
‘At the moment, we’re holding the leading position as the largest data management company with the richest product pipeline in Russia. We know that our clients in EU and US are waiting for us, and our growth and experience of working with international companies convinced us to launch Data MATRIX in Europe. We chose Munich as the heart of the European biotech. We believe that the local professional market players with their in-depth understanding of the industry will recognize a reliable partner in Data MATRIX’, – says company’s CEO Ivan Dobromyslov.
Data MATRIX employees are proud to be members of the professional communities, which unite data managers (ACDM, SCDM), biostatisticians (ISBC), and medical writers (EMWA, AMWA). In February 2017, Data MATRIX also became a member of CDISC, whose standards regarding data management, statistical analysis, and medical documentation were strictly followed since the very beginning. The company is enhanced with a team of top industry experts within the Advisory board.
The company has been working with clinical data since 2009. The software applications are developed in-house by Data MATRIX, fully validated, 21 CFR part 11 and CDISC compliant. As of today, the team has conducted 134 projects for pharmaceutical and biotech companies and CROs.
With Data MATRIX products, 6 out of 10 TOP Big Pharma companies have already reduced their R&D costs by 15%. The company recently raised the investments for further development and expansion to EU ad US markets.
‘At the moment, we’re holding the leading position as the largest data management company with the richest product pipeline in Russia. We know that our clients in EU and US are waiting for us, and our growth and experience of working with international companies convinced us to launch Data MATRIX in Europe. We chose Munich as the heart of the European biotech. We believe that the local professional market players with their in-depth understanding of the industry will recognize a reliable partner in Data MATRIX’, – says company’s CEO Ivan Dobromyslov.
Data MATRIX employees are proud to be members of the professional communities, which unite data managers (ACDM, SCDM), biostatisticians (ISBC), and medical writers (EMWA, AMWA). In February 2017, Data MATRIX also became a member of CDISC, whose standards regarding data management, statistical analysis, and medical documentation were strictly followed since the very beginning. The company is enhanced with a team of top industry experts within the Advisory board.